Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18877419 | 0.75 | SMN1; SMN2 (0.41) | POLB | |
| SCHEMBL8594034 | 0.75 | MME (0.42) | MMECA2FOLH1ACECPA1 | |
| SCHEMBL3517847 | 0.74 | NOD1 (0.52) | MMECA2NOD1FNTAFNTB | |
| SCHEMBL7996278 | 0.74 | FOLH1 (0.44) | MMECA2FOLH1 | |
| SCHEMBL10037495 | 0.74 | SLC1A2 (0.42) | — | |
| SCHEMBL12107536 | 0.73 | CYP1A2 (0.43) | POLB | |
| SCHEMBL25189496 | 0.73 | SMN1; SMN2 (0.43) | MMEACEPOLB | |
| SCHEMBL43970 | 0.72 | PTPN1 (0.42) | CA2POLB | |
| SCHEMBL15757005 | 0.72 | DPP7 (0.58) | MMECA2NOD1 | |
| SCHEMBL29476436 | 0.72 | DPP7 (0.58) | MMECA2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727720-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2155894-A2 | TARGETING HOST PROTEINASES AS A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL PATHOGENS | Burnham Institute for Medical Research (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2091964-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | Southern Research Institute (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009023306-A2 | TARGETING HOST PROTEINASES AS A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL PATHOGENS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-19 | — | — | WO | disclosed |
| US-7442506-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008054726-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | SOUTHERN RESEARCH INSTITUTE (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20070178478-A1 | Methods for detection of genetic disorders | RAVGEN, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20060160105-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060121452-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-06-08 | — | — | US | disclosed |